Form 4: Revolution Medicines Executive Sells Shares
Insider Transaction (Form 4)
Alan B. Sandler, Chief Development Officer of Revolution Medicines, Inc., sold 6,309 shares of common stock on September 29, 2026.
Summary
- Option exercise/conversion: acquired 6,000 Common Stock at $58.84 ($353,040) on September 29, 2026; holds 58,868 after (Direct).
- Open-market sale: disposed of 2,200 Common Stock at $200.82 ($441,801) on September 29, 2026; holds 56,668 after (Direct).
- Open-market sale: disposed of 1,609 Common Stock at $201.72 ($324,574) on September 29, 2026; holds 55,059 after (Direct).
- Open-market sale: disposed of 1,000 Common Stock at $202.81 ($202,813) on September 29, 2026; holds 54,059 after (Direct).
- Open-market sale: disposed of 1,199 Common Stock at $203.91 ($244,485) on September 29, 2026; holds 52,860 after (Direct).
- Open-market sale: disposed of 301 Common Stock at $204.72 ($61,621) on September 29, 2026; holds 52,559 after (Direct).
- Option exercise/conversion: disposed of 6,000 Stock Option (Right to Buy) on September 29, 2026; holds 161,300 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,275,294 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Alan B. Sandler — Officer (Chief Development Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-29 | Option exercise/conversion | Common Stock | 6,000 | $59 | $353.0K | 58,868 |
| 2026-09-29 | Open-market sale | Common Stock | 2,200 | $201 | $441.8K | 56,668 |
| 2026-09-29 | Open-market sale | Common Stock | 1,609 | $202 | $324.6K | 55,059 |
| 2026-09-29 | Open-market sale | Common Stock | 1,000 | $203 | $202.8K | 54,059 |
| 2026-09-29 | Open-market sale | Common Stock | 1,199 | $204 | $244.5K | 52,860 |
| 2026-09-29 | Open-market sale | Common Stock | 301 | $205 | $61.6K | 52,559 |
| 2026-09-29 | Option exercise/conversion | Stock Option (Right to Buy) | 6,000 | — | — | 161,300 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-29 | Option exercise/conversion (6,000 shares) |
| 2026-09-29 | Open-market sale (2,200 shares) |
| 2026-09-29 | Open-market sale (1,609 shares) |
| 2026-09-29 | Open-market sale (1,000 shares) |
| 2026-09-29 | Open-market sale (1,199 shares) |
| 2026-09-29 | Open-market sale (301 shares) |
| 2026-09-29 | Option exercise/conversion (6,000 shares) |
Keywords
insider transaction, Form 4, RVMD, Revolution Medicines, Inc., bearish, Alan B. Sandler
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.